从基础到临床:自身免疫性大疱性疾病不断演变的治疗靶点
本综述聚焦自身免疫性大疱性疾病,包括天疱疮、类天疱疮及获得性大疱性表皮松解症。文章系统梳理了靶向B细胞清除、T调节细胞补充、细胞信号抑制剂、小分子抑制剂、抑制性单克隆抗体及补体抑制等新型治疗策略,并评述其当前临床证据水平。这些源于基础科学发现的新兴疗法有望变革该类疾病的治疗范式。
要点
- 自身免疫性大疱性疾病由针对表皮和表皮下黏附蛋白的自身抗体介导,传统治疗依赖全身免疫抑制。
- 新型治疗策略涵盖B细胞清除、T调节细胞补充、信号通路抑制、补体抑制等靶向通路。
- 实验性获得性大疱性表皮松解症小鼠模型可提供额外的治疗靶点线索。
核心结论
- 靶向特定通路的新型疗法有望变革自身免疫性大疱性疾病的治疗范式。
研究设计与样本
- 综述,总结天疱疮和类天疱疮病理生理学进展及由此开发的新型治疗策略,并评述其临床证据水平。
主要发现
- 新型策略包括B细胞清除、T调节细胞补充、细胞信号抑制剂和小分子抑制剂、抑制性单克隆抗体以及补体抑制。
- 实验性获得性大疱性表皮松解症小鼠模型提供了额外的治疗靶点。
临床怎么用
- 传统治疗依赖全身免疫抑制,新型靶向疗法为自身免疫性大疱性疾病提供了潜在的新选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoimmune blistering diseases comprise a group of heterogenous conditions characterized by the loss of tolerance and subsequent development of autoantibodies targeting epidermal and subepidermal adhesion proteins. Blisters and erosions form on the skin and mucous membranes leading to significant morbidity and mortality. Traditional therapies rely on systemic immunosuppression. Advancements in our understanding of the pathophysiology of pemphigus and pemphigoid have led to the development of molecules which target specific pathways involved in induction and perpetuation of disease. In this review, we outline the novel therapeutic strategies including B-cell depletion, T-regulatory cell repletion, cell signalling inhibitors and small molecular inhibitors, inhibitory monoclonal antibodies, as well as complement inhibition. We additionally review their current level of clinical evidence. We lastly review therapeutics targets gleaned from the experimental epidermolysis bullosa acquisita mouse model. These emerging treatments offer an exciting progression from basic science discoveries that have the potential to transform the treatment paradigm in autoimmune blistering diseases.
引用
- Kridin K, Kowalski EH, Kneiber D, et al. From bench to bedside: evolving therapeutic targets in autoimmune blistering disease. J Eur Acad Dermatol Venereol. 2019. PMID: 31314932. doi:10.1111/jdv.15816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。